Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Cancer Res. 2017 Jul 6;77(18):4846–4857. doi: 10.1158/0008-5472.CAN-17-0282

Figure 6. WNT activation is seen in higher risk subtypes of human MDS and is associated with worse overall survival.

Figure 6

Expression of WNT target genes were evaluated in 183 MDS marrow derived CD34+ samples when compared to healthy controls and representative candidates are shown (A). WNT score based on degree of activation of target genes is significantly elevated in higher risk RAEB subtypes when compared to lower risk RA and RARS subtypes (TTest, * P Value<0.05)(B). MDS patients with high WNT score (above median) have a worse overall survival (median survival = 2.95 years) when compared to those with low WNT score (median survival = 5.24 years)(Log rank P Value =0.037).